Taletrectinib adipate is under clinical development by AnHeart Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Taletrectinib adipate’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 04 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Taletrectinib adipate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Taletrectinib adipate overview

Taletrectinib (DS-6051b/AB-106) is under development for the treatment of relapsed or refractory solid tumors including k-RAS wild-type colorectal cancer, neuroendocrine tumors, non-small-cell lung carcinoma (NSCLC), primary CNS tumors, brain metastases and pulmonary large-cell neuroendocrine carcinoma (LCNEC). It is administered orally as a capsule. The drug candidate targets tyrosine kinases ROS1 and NTRKs type 1, 2, 3.

AnHeart Therapeutics overview

AnHeart Therapeutics is a clinical stage biopharmaceutical company that focuses on oncology drugs to address unmet medical needs and underserved markets. The company is headquartered in New York City, New York, the US.

Quick View Taletrectinib adipate LOA Data

Report Segments
  • Innovator
Drug Name
  • Taletrectinib adipate
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.